GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Shiller PE Ratio

Avalo Therapeutics (STU:C6K0) Shiller PE Ratio : (As of May. 05, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Avalo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Shiller PE Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avalo Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avalo Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Avalo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Shiller PE Ratio falls into.


;
;

Avalo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Avalo Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Avalo Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-3.207/133.1571*133.1571
=-3.207

Current CPI (Dec. 2024) = 133.1571.

Avalo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -1,861.638 99.621 -2,488.331
201506 -1,614.969 100.684 -2,135.839
201509 -205.525 100.392 -272.604
201512 -1,401.235 99.792 -1,869.725
201603 -1,525.882 100.470 -2,022.307
201606 -1,050.912 101.688 -1,376.133
201609 -1,796.256 101.861 -2,348.143
201612 -491.443 101.863 -642.425
201703 -511.632 102.862 -662.317
201706 -358.848 103.349 -462.347
201709 1,256.486 104.136 1,606.655
201712 -559.728 104.011 -716.575
201803 -280.282 105.290 -354.466
201806 -468.403 106.317 -586.654
201809 -1,752.394 106.507 -2,190.883
201812 -379.728 105.998 -477.023
201903 -331.344 107.251 -411.381
201906 -280.368 108.070 -345.454
201909 -183.053 108.329 -225.006
201912 77.760 108.420 95.502
202003 -886.176 108.902 -1,083.554
202006 -485.914 108.767 -594.875
202009 -415.670 109.815 -504.025
202012 -426.125 109.897 -516.317
202103 -774.144 111.754 -922.405
202106 -420.311 114.631 -488.238
202109 -424.320 115.734 -488.198
202112 -409.932 117.630 -464.045
202203 -512.112 121.301 -562.166
202206 -313.315 125.017 -333.716
202209 82.416 125.227 87.635
202212 -235.434 125.222 -250.353
202303 -190.536 127.348 -199.228
202306 -129.894 128.729 -134.362
202309 -25.140 129.860 -25.778
202312 -9.342 129.419 -9.612
202403 -129.720 131.776 -131.079
202406 -3,137.047 132.554 -3,151.325
202409 -2.550 133.029 -2.552
202412 -3.207 133.157 -3.207

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avalo Therapeutics  (STU:C6K0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Avalo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Headlines

No Headlines